Navigation Links
Questcor Pharmaceuticals to Present at the Leerink Swann Global Healthcare Conference on February 16, 2012
Date:2/10/2012

ANAHEIM, Calif., Feb. 10, 2012  /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) announced today that executive management will present at the Leerink Swann Global Healthcare Conference to be held on February 15-16, 2012 in New York.  Steve Cartt, Executive Vice President and Chief Business Officer, is scheduled to present an overview of the Company on Thursday, February 16, 2012 at 2:30 p.m. ET. 

A live webcast and subsequent archived replay of the presentation will be accessible at http://ir.questcor.com/events.cfm.  The replay will be available for 90 days after the event.

About Questcor                                                                                     

Questcor Pharmaceuticals, Inc. is a biopharmaceutical company whose primary product, Acthar, helps patients with serious, difficult-to-treat medical conditions.  Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications.  Of these 19 indications, Questcor currently generates substantially all of its net sales from three indications: the treatment of acute exacerbations of multiple sclerosis in adults, the treatment of nephrotic syndrome, and the treatment of infantile spasms in children under two years of age. With respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus."  Questcor is also exploring the use of Acthar to treat systemic lupus erythematosus, or SLE, for which Acthar is approved as both a maintenance therapy and to treat exacerbations.  Questcor is also exploring the possibility of developing markets for other on-label indications and the possibility of pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need.  In October 2011, Forbes magazine ranked Questcor number one in its annual rankings of America's Best Small Companies.  For more information, please visit www.questcor.com.


'/>"/>
SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Questcor Announces Third Quarter 2010 Earnings Release Date and Conference Call
2. Questcor Pharmaceuticals to Be Added to S&P SmallCap 600 Index
3. Questcor Pharmaceuticals to Present at the Jefferies Global Healthcare Conference on June 9, 2011
4. Questcor Pharmaceuticals to Present at Upcoming Investor Conferences in September
5. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
6. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
7. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
8. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
9. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
10. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
11. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... (PRWEB) , ... February 16, 2017 , ... Avomeen & ... The event will be held at Avomeen Analytical Services (4840 Venture Dr., Ann ... MichBio member organization. They provide an opportunity to interact with peers, make new connections ...
(Date:2/16/2017)... Calif. , Feb. 16, 2017  ArmaGen, ... developing groundbreaking therapies to treat severe neurological disorders, ... children treated with AGT-181, the company,s investigational therapy ... (also known as mucopolysaccharidosis type I, or MPS ... 2 proof-of-concept (POC) study, presented today at the ...
(Date:2/16/2017)... 16, 2017 Patient Care ... innovative telemedicine application, new and leading edge therapies ... a boom worldwide. The healthcare sector as whole ... services and new therapies for companies such as ... Cellectar Biosciences, Inc. (NASDAQ: CLRB ), ...
(Date:2/16/2017)... Malden, MA (PRWEB) , ... February 16, 2017 ... ... viscoelastic 4-level cervical case. Dr. Kingsley Chin, professor and Harvard trained surgeon, completed ... The procedure was performed on a 55-year-old practicing female physician suffering from degenerative ...
Breaking Biology Technology:
(Date:2/2/2017)... Feb. 2, 2017   TapImmune, Inc. ... company specializing in the development of innovative peptide ... of cancer and metastatic disease, announced today it ... manufacturing of a second clinical lot of TPIV ... receptor alpha. The manufactured vaccine product will be ...
(Date:1/30/2017)... , Jan. 30, 2017   Invitae Corporation ... fastest growing genetic information companies, today announced that it ... results and provide 2017 guidance on Monday, February 13, ... call that day at 4:45 p.m. Eastern / 1:45 ... management team will briefly review financial results, guidance, and ...
(Date:1/24/2017)... , Jan. 24, 2017  It sounds simple ... sock that monitors vital signs and alerts parents ... infant,s oxygen saturation level drops. But pediatric experts ... to parents, with no evidence of medical benefits, ... are marketed aggressively to parents of healthy babies, ...
Breaking Biology News(10 mins):